In BRAF-mutated MM subjects, several PET-derived parameters (MTV, TLG) have been successfully applied for prognostic stratification prior to molecularly targeted therapy and to assess metabolic response during treatment. This evidence concerns the gene BRAF and Miyoshi myopathy.